Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/11050
SEOM Clinical guidelines for the treatment of metastatic prostate cancer
StatisticsItem usage statistics
MetadataShow Dublin Core item record
Document typeresearch article
CitationCassinello J, Climent MA, Gonzalez Del Alba A, Mellado B, Virizuela JA. SEOM Clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol. 2014 Dec;16(12):1060-6. Epub 2014 Oct 16.
Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged: pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently required.
KeywordsAndrogen deprivation treatment
Castration-resistant prostate cancer
This item appears in following Docusalut collectionsHospital Universitario Son Espases - HUSE > Comunicación científica
Instituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica